ArticleJournal of pain research2025
Comparative Cardiovascular Safety of Duloxetine and Gabapentin in Patients with Hip Osteoarthritis.
Article in Journal of pain research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Duloxetine, an antidepressant commonly used as a nonopioid analgesic for chronic pain management, has been speculated to increase cardiovascular (CV) complications. This study aims to evaluate the CV and mortality risks associated with duloxetine compared to gabapentin in patients with hip osteoarthritis (OA). Methods: In this population-based, retrospective cohort study using Korean health insurance data (2013-2022), we evaluated the cardiovascular risk of duloxetine versus gabapentin in patients with hip osteoarthritis, applying inverse probability of treatment weighting (IPTW) with adjustment methods, with outcomes included composite cardiovascular events, major cardiovascular events (MACE), stroke, heart failure, and acute myocardial infarction (AMI). Results: A total of 3383 and 18,874 patients were included in the duloxetine and gabapentin groups, respectively, with a mean follow-up of 4.1 years. The composite outcomes risk was higher with duloxetine than with gabapentin (HR 1.10; 95% CI, 1.03-1.17). Duloxetine was associated with increased risk of MACE (HR 1.15; 95% CI, 1.06-1.27), hemorrhagic stroke (HR 1.52; 95% CI, 1.23-1.86), and heart failure (HR 1.19; 95% CI, 1.05-1.34), whereas a lower risk was observed for AMI (HR 0.65, 95% CI, 0.52-0.82). In our subgroup analysis of patients with no baseline cardiovascular diseases (CVDs), duloxetine users had a higher likelihood of experiencing composite outcomes (HR 1.29), MACE (1.41), hemorrhagic stroke (HR 1.79), ischemic stroke (HR 1.18), and heart failure (HR 1.44) compared to gabapentin users. Conclusion: Duloxetine was generally associated with increased CV risks, while a lower risk of AMI and no significant increase in mortality were observed compared to gabapentin. Our subgroup analysis further suggests that when potential confounding from preexisting CVDs was minimized, duloxetine was associated with incident CV complications in patients without prior CVDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.